search
Back to results

Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes (INFORM)

Primary Purpose

Atherosclerosis, Leukocyte Activation Disorder, Type 2 Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
OGTT
Sponsored by
Sint Franciscus Gasthuis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Atherosclerosis

Eligibility Criteria

45 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Provide written informed consent
  • Aged 45-65 years
  • BMI < 35 kg/m2

Exclusion Criteria:

  • Emotionally and intellectually not capable to decide about participation in the study and the consequences of participation. Subjects who are not able to understand the patient information
  • Diabetes mellitus treated with oral antidiabetic medicine
  • Type 1 diabetes mellitus
  • Peripheral artery and/or coronary disease
  • Untreated hypertension
  • Alcohol use > 2 units/day
  • Aberrations in kidney, liver and thyroid function
  • Use of any experimental medication within 6 months of the study
  • The use of immunosuppressive drugs

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Active Comparator

    Active Comparator

    Active Comparator

    Active Comparator

    Arm Label

    T2DM

    FCH

    FH

    Healthy controls

    Arm Description

    Patients with type 2 diabetes mellitus, defined as having met the diagnostic criteria as outlined by the World Health Organization

    Patients with familial combined hyperlipidemia, defined as familial hyperlipidemia with a dominant inheritance pattern, elevated plasma apolipoprotein (apo) B concentrations (>1.2 g/L) and elevated triglyceride (TG) levels (>1.7 mmol/L) at the time of diagnosis

    Patients with familial hyperlipidemia, defined as having met the diagnostic criteria as outlined by the world Health Organization

    Healthy controls

    Outcomes

    Primary Outcome Measures

    Postprandial change in leukocyte activation
    Leukocyte activation is determined by flow cytometry, using fluorescent labelled antibodies: FITC-conjugated anti-CD66b and PE-conjugated anti-CD11b, expressed in mean fluorescence intensity in arbitrary units. The difference in postprandial response, expressed as area under the curve, between patients with T2DM, FCH and healthy controls is determined using ANOVA.

    Secondary Outcome Measures

    Correlation between chronic glycemia and leukocyte activation
    To assess whether chronic hyperglycemia (HbA1c) correlates with postprandial leukocyte activation, correlation between HbA1c and postprandial leukocyte activation (area under the curve) will be determined for the total study group.
    Correlation between acute glycemia and leukocyte activation
    To assess whether acute hyperglycemia correlates with postprandial leukocyte activation, correlation between fasting glucose levels and postprandial leukocyte activation (area under the curve) will be determined for the total study group.

    Full Information

    First Posted
    April 21, 2014
    Last Updated
    May 1, 2014
    Sponsor
    Sint Franciscus Gasthuis
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02130505
    Brief Title
    Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes
    Acronym
    INFORM
    Official Title
    Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    June 2007 (undefined)
    Primary Completion Date
    June 2008 (Actual)
    Study Completion Date
    June 2008 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Sint Franciscus Gasthuis

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    In this study, we will investigate both inflammatory systems in healthy volunteers and patients with T2DM on insulin therapy and hyperlipidemia (both familial hyperlipidemia (FH) and familial combined hyperlipidemia (FCH)) during an OGTT.
    Detailed Description
    Cardiovascular disease (CVD) is number one killer in the Netherlands. Insulin resistance and dyslipideima are the main causes of CVD. Recently, we have shown that there is an acute leukocyte activation after an oral glucose tolerance test (OGTT) in patients with newly-diagnosed diabets mellitus type 2 (T2DM). Leukocyte activation is an important and obligatory aspect in the process of atherosclerosis. Complement system is another important inflammatory component in atherosclerosis, which becomes activated in the postprandial phase. In this study, we will investigate both inflammatory systems in healthy volunteers and patients with T2DM on insulin therapy and hyperlipidemia (both familial hyperlipidemia (FH) and familial combined hyperlipidemia (FCH)) during an OGTT.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Atherosclerosis, Leukocyte Activation Disorder, Type 2 Diabetes Mellitus, Familial Combined Hyperlipidemia

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    51 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    T2DM
    Arm Type
    Active Comparator
    Arm Description
    Patients with type 2 diabetes mellitus, defined as having met the diagnostic criteria as outlined by the World Health Organization
    Arm Title
    FCH
    Arm Type
    Active Comparator
    Arm Description
    Patients with familial combined hyperlipidemia, defined as familial hyperlipidemia with a dominant inheritance pattern, elevated plasma apolipoprotein (apo) B concentrations (>1.2 g/L) and elevated triglyceride (TG) levels (>1.7 mmol/L) at the time of diagnosis
    Arm Title
    FH
    Arm Type
    Active Comparator
    Arm Description
    Patients with familial hyperlipidemia, defined as having met the diagnostic criteria as outlined by the world Health Organization
    Arm Title
    Healthy controls
    Arm Type
    Active Comparator
    Arm Description
    Healthy controls
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    OGTT
    Intervention Description
    Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
    Primary Outcome Measure Information:
    Title
    Postprandial change in leukocyte activation
    Description
    Leukocyte activation is determined by flow cytometry, using fluorescent labelled antibodies: FITC-conjugated anti-CD66b and PE-conjugated anti-CD11b, expressed in mean fluorescence intensity in arbitrary units. The difference in postprandial response, expressed as area under the curve, between patients with T2DM, FCH and healthy controls is determined using ANOVA.
    Time Frame
    area under the curve during 2 hours
    Secondary Outcome Measure Information:
    Title
    Correlation between chronic glycemia and leukocyte activation
    Description
    To assess whether chronic hyperglycemia (HbA1c) correlates with postprandial leukocyte activation, correlation between HbA1c and postprandial leukocyte activation (area under the curve) will be determined for the total study group.
    Time Frame
    area under the curve during 2 hours
    Title
    Correlation between acute glycemia and leukocyte activation
    Description
    To assess whether acute hyperglycemia correlates with postprandial leukocyte activation, correlation between fasting glucose levels and postprandial leukocyte activation (area under the curve) will be determined for the total study group.
    Time Frame
    area under the curve during 2 hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    45 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Provide written informed consent Aged 45-65 years BMI < 35 kg/m2 Exclusion Criteria: Emotionally and intellectually not capable to decide about participation in the study and the consequences of participation. Subjects who are not able to understand the patient information Diabetes mellitus treated with oral antidiabetic medicine Type 1 diabetes mellitus Peripheral artery and/or coronary disease Untreated hypertension Alcohol use > 2 units/day Aberrations in kidney, liver and thyroid function Use of any experimental medication within 6 months of the study The use of immunosuppressive drugs
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Manuel Castro Cabezas, MD, PhD
    Organizational Affiliation
    Sint Franciscus Gasthuis
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    25456098
    Citation
    de Vries MA, Alipour A, Klop B, van de Geijn GJ, Janssen HW, Njo TL, van der Meulen N, Rietveld AP, Liem AH, Westerman EM, de Herder WW, Cabezas MC. Glucose-dependent leukocyte activation in patients with type 2 diabetes mellitus, familial combined hyperlipidemia and healthy controls. Metabolism. 2015 Feb;64(2):213-7. doi: 10.1016/j.metabol.2014.10.011. Epub 2014 Oct 16.
    Results Reference
    derived

    Learn more about this trial

    Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes

    We'll reach out to this number within 24 hrs